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Tumor necrosis factor-a; Gene polymorphism; Asian Indians; Obesity Summary Background: Obstructive sleep apnea (OSA) is emerging as a significant disorder in India. Tumor necrosis factor-a (TNFa) is an important marker of inflammation. Recent data indicate that inflammation may be an important correlate of OSA. The relationships of OSA with TNFa levels and TNFa gene promoter polymorphism (À308G/A) have not been investigated in obese Asian Indians with OSA. Objective: To look for the correlation if any, between TNFa gene promoter polymorphism (À308G/A) in obese Asian Indians with and without OSA and correlation of TNFa levels with severity of OSA. Methods and results: We studied 207 obese (BMI > 25 kg/m 2 ) subjects; 104 with OSA and 103 without OSA. Both groups were matched for age, body mass index (BMI) and percentage body fat (%BF). Measurements included anthropometric and biochemical (fasting blood glucose, lipid profile and serum TNFa levels) parameters and TNFa gene promoter polymorphism (À308G/A). The frequency of 'À308A' allele in TNFa gene was significantly higher in obese subjects with OSA (28.8%; 60/208), when compared with obese subjects without OSA (12.6%; 26/206, p Z 0.001). Serum TNFa levels were significantly higher in obese subjects with OSA [(3.6 AE 0.8)pg/ml], when compared with obese subjects without OSA [(3.3 AE 0.6)pg/ml, p Z 0.009].
Introduction
Obstructive sleep apnea (OSA) is a disorder characterized by repetitive collapse of upper airway during sleep. It affects about 4e9% of adult population and children. 1 Prevalence of OSA is 7.5% in Asian Indians living in India. 2 OSA is now considered as an independent risk factor for hypertension and cardiovascular mortality. 3, 4 There is increasing evidence that OSA is associated with inflammation. TNFa (À308G/A) polymorphism is associated with increased TNFa levels. 5, 6 Derangements of inflammatory cytokines, such as C-reactive protein (CRP) and interleukin-6 (IL-6) have been reported in OSA. 7, 8 Tumor necrosis factor-a (TNFa), a pro-inflammatory cytokine may have a role in regulation of sleep. 9, 10 Excessive daytime sleepiness (EDS), a major feature of OSA, is promoted by increase in TNFa levels. 7, 9 Ryan et al. have shown that intermittent hypoxia is a strong predictor of serum TNFa levels. 11 The primary risk factor for OSA is excessive weight gain. Other than male gender, obesity is the strongest risk factor for the development of OSA. 12, 13 Various studies indicate that about 66% of patients with OSA are obese. Significant weight loss has been shown to have varying degrees of improvement in OSA. 14 Previous studies on Asian Indians with OSA are limited to assessment of prevalence data, evaluation of relationship of OSA with road traffic accidents and public health awareness of OSA. 2, 15, 16 Data regarding relationship of sub-clinical inflammation and OSA are limited. Recently, we have shown the association of severity in OSA with increasing levels of CRP in obese Asian Indians. 17 The relationship of TNFa levels and its promoter polymorphism (À308G/A) has not been investigated in Asian Indians with OSA. Since high levels of TNFa have been linked to EDS, 11 it is possible that TNFa (À308G/A) promoter polymorphism may associate with the development of OSA in obese Asian Indians with OSA.
We conducted this cross-sectional study to determine the frequency of TNFa (À308A) allele in obese subjects with and without OSA. Correlation, if any, of serum TNFa levels with OSA severity was also looked at in these obese subjects.
Methods Subjects
A total of 207 obese subjects were recruited from Medicine out patients department of All India Institute of Medical Sciences, a tertiary care referral hospital. The subjects were North Indians residing in New Delhi or surrounding areas located near New Delhi. 104 obese subjects were newly diagnosed with OSA (84 males and 20 females) and 103 obese subjects were without OSA (65 males and 38 females). To nullify the effect of obesity, subjects were carefully matched for age, body mass index (BMI) and percentage body fat (%BF). Full montage polysomnography (PSG) was performed in all subjects. On the basis of apnea-hypopnea index (AHI), subjects were categorized as with or without OSA (see definitions below). All subjects were free of any acute or apparent chronic inflammatory disorders, chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD; based on clinical history and ECG). Subjects with other sleep disorders such as upper airway resistance syndrome (UARS), central sleep apnea (CSA), periodic limbs movement (PLMs) or narcolepsy were excluded. All subjects were nonsmokers or had quit smoking before three years. No subject was taking any medications at the time of evaluation. Clinical evaluation for all subjects included thyroid profile and an ECG was done on enrollment. The study was approved by institutional ethics committee and written informed consent was obtained from all subjects.
Metabolic parameters
Blood samples were collected after an overnight fast for estimation of fasting blood glucose (FBG) and blood lipoproteins. Levels of FBG, total cholesterol (TC) and serum triglycerides (TG) were estimated using commercial kits (Randox Laboratory, San Francisco, CA, USA) in a semiautomated analyzer (Micro Semi-Autoanalyser 2000, C.L. Micromed, Italy).
Anthropometric measurements
The anthropometric measurements were carried out by a physician according to methods described earlier. 18 Briefly, waist circumference was measured midway between the highest point of superior iliac crest and lowest point of costal margin; hip circumference was measured at the maximum circumference of buttocks. All measurements were taken in standing position with feet placed together. Measurement of % BF was carried out using leg-to-leg (two point contact) bioelectrical impedance method (Tanita TBF 300, TANITA Corp., Tokyo, Japan). For estimation of bioelectrical impedance, subjects were evaluated after an overnight fast. They were instructed to avoid fluid intake and void urine 1 h prior to measurements and just before the test. Gender and height details were manually entered into the system. Subjects were instructed to stand on apparatus so that both feet were in firm contact with the surface of apparatus and hands were not in touch with any surface.
Polysomnography (PSG)
All subjects underwent overnight digital full montage PSG (Medi palm; Braebon Medical Corp., Canada) and classified according to AHI (see definitions). Digital PSG included electrooculogram, electroencephalogram, electromyogram, electrocardiogram, airflow (with an oro-nasal thermistor), chest and abdominal efforts and arterial oxyhemoglobin saturation by pulse oximeter. The recordings were done using pursuit recording device and studies were analyzed at 30 s epochs. Sleep study analysis and sleep stages were scored according to standard criteria of Rechtschaffen and Kales manual. 19, 20 Obstructive apneas and hypopneas were typically distinguished from central events by detection of respiratory efforts during event.
Definitions
Obesity was defined as BMI > 25 kg/m 221 and morbid obesity was defined as BMI > 40 kg/m 2 . 22 Diagnosis of OSA was made on the basis of international classification of sleep disorders. 23 Breathing event was defined according to the commonly used clinical criteria published by American Academy of Sleep Medicine Task Force. 20 Apnea was defined as cessation of airflow ! 10 s. Hypopnea was defined as recognizable, transient reduction of breathing ! 10 s associated with either an oxygen desaturation of !4% or an arousal. AHI was defined as number of obstructive apneas and hypopneas per hour of sleep. Subjects with an AHI < 5/h were assigned as not having OSA and subjects with an AHI ! 10/h were diagnosed to have OSA. Subjects having AHI between 5 and 10/h were not included in the analysis to maintain a clear distinction between subjects with and without OSA. Subjects having OSA were further classified as mild (AHI 10e15/h), moderate (AHI 15e30/h) and severe (AHI > 30/h) OSA. Epworth sleepiness scale (ESS) was used to check excessive sleepiness. 24 A total score of less than 10 suggested that a person was not suffering from excessive sleepiness. ESS greater than or equal to 10 was used to make the diagnosis of OSA.
Serum TNFa levels
Blood samples for estimating serum levels of TNFa were collected in the morning between 8 am and 9 am in all subjects. Serum TNFa levels in all subjects were measured by enzyme-linked immunosorbent assay (ELISA) based kits and according to the manufacturers' instructions (eBiosciences, San Diego, CA). The sensitivity range of the kit is from 4 to 500 pg/ml. The intra-assay variation was 2.0e 2.5% and inter-assay variation was 3e3.5%.
TNFa promoter polymorphism (À308G/A)
Venous blood sample (10 ml) was drawn into EDTA containing tubes for DNA isolation. Genomic DNA was extracted from leucocytes after lysing erythrocytes from cell pellet. DNA was liberated by sodium dodecyl sulphate (SDS) and proteinase-K after overnight digestion at 37 C. 25 Proteins were removed by addition of 5 M NaCl, and DNA was recovered by ethanol precipitation.
The polymorphic variants of TNFa gene promoter region (À308G/A) were determined by polymerase chain reactionerestriction fragment length polymorphism (PCRe RFLP). The upstream primer sequence was 5 0 AGGCAA TAGGTTTTGAGGGCCAT3 0 and downstream primer sequence was 5 0 TCCTCCCTGCTCCGATTCCG3 0 . The reaction was carried out in a final volume of 25 ml containing 0.25 mM of each dNTP (Bangalore Genei, India), 0.1 mmol of each primer and 1.25 U of Taq DNA polymerase (Bangalore Genei, India). DNA was amplified during 35 cycles with 1 min denaturation at 94 C, 1 min annealing at 60 C and 1 min extension at 72 C. Initially, 1 cycle of denaturation at 94 C, 1 min annealing at 60 C and 1 min extension at 72 C was performed. Finally, a cycle of 1 min denaturation at 94 C, 1 min annealing at 60 C and 5 min extension at 72 C was included. The PCR product was digested with 0.5 ml of NcoI restriction enzyme (New England Biolabs). After restriction digestion, three bands of different sizes were obtained. 107 bp fragment corresponding to variant allele (Restriction site absent) and a set of 87 bp and 20 bp corresponding to wild type allele (Restriction site present). Band pattern was checked by using 10% native polyacrylamide gel electrophoresis (PAGE) followed by silver staining.
Statistical methods
Data were managed using an Excel spreadsheet (Microsoft Corp., Washington, USA). Mean and standard deviation (S.D.) are used as summary measures. Due to high range of TNFa levels in samples, values are expressed as Log values. Student's 't' test was applied using parametric method to compare mean values between subjects with and without OSA. In case of high standard deviation, nonparametric test was used. ANOVA, followed by multiple comparisons (post hoc test) was used to compare mean values of parameters between subjects without OSA and subjects with various levels in severity of OSA. Multiple logistic regression analysis was done to check the effect of gender and other variables on TNFa levels. Power of the study was determined using STATA statistical software. The HardyeWeinberg equilibrium was tested by using (p 2 þ 2pqþq 2 Z 1) formula. SPSS (Chicago, version 15) statistical software was used for data analysis and p < 0.05 was considered as statistically significant. Table 1 shows characteristics and TNFa levels of subjects with and without OSA. There was no significant difference in the mean values of age, BMI, %BF, waist circumference and hip circumference in these groups. The mean values of neck circumference, calf circumference, diastolic blood pressure, FBG levels and the blood glucose levels 2-h after 75 g oral glucose load were significantly higher in subjects with OSA, when compared with subjects without OSA. There was no significant difference in total cholesterol (TC) and triglyceride (TG) levels in subjects with and without OSA. Serum TNFa levels were significantly higher in subjects with OSA as compared to subjects without OSA. Table 2 shows the ESS and polysomnography profile of subjects with and without OSA. The frequency of TNFa (À308A) allele was significantly higher in obese subjects with OSA (28.8%), when compared with obese subjects without OSA (12.6%; p Z 0.001; Subjects with OSA having TNFa (À308A) allele were having a significantly higher value of waist circumference, neck circumference, systolic blood pressure, mean SpO 2 , ESS and TNFa levels when compared with subjects without OSA having TNFa (À308A) allele. Mean levels of TC, TG and HDL-C were comparable between these two groups ( Logistic regression analysis was done by adjusting for FBG, 2 h-BG and diastolic blood pressure variables. It showed that TNFa (À308A) allele frequency and TNFa levels were higher in subjects with OSA [OR (95% CI) 2.1(1.2e3.7), p Z 0.008 and 1.6(1.1e2.4), p Z 0.009 respectively]. It was also found that gender difference was not a confounding factor for increased TNFa levels in these subjects [1.0(0.9e1.0); p Z 0.14)].
Results
Discussion
This study is the first attempt to look at the TNFa gene promoter polymorphism (À308G/A) and relationship of severity in OSA with serum TNFa levels in obese Asian Indians with OSA. In Indian context, previous studies on TNFa levels and its gene polymorphism have been conducted in diabetes, asthma and inflammatory bowel disease. 26e28 Our study shows that, even after excluding effects of age, BMI and %BF, subjects with OSA have significantly higher serum TNFa levels, when compared with those without OSA. Furthermore, increase in serum TNFa levels demonstrated a stepwise increase with severity of OSA.
Significant increase in AHI, TNFa levels and significant decrease in SpO 2 levels in subjects with OSA having 'À308A' allele than 'À308G' allele suggests that TNFa (À308A) allele may be a risk factor for OSA in these subjects.
Two previous studies have looked at TNFa gene polymorphism in OSA subjects. 29, 30 Riha et al. (2005) reported an association of TNFa gene polymorphism (À308A) carriage with obstructive sleep apnea in 206 subjects in UK. 29 Serum levels of TNFa were not measured in this study. Liu et al. (2006) , in a small study (n Z 18) reported that plasma levels of TNFa were significantly higher in Chinese subjects having OSA, when compared with controls. 30 These authors opined that TNFa gene (À308A) allele might lead to susceptibility for OSA. In the present study, the frequency of TNFa gene (À308A) allele was twice as high in subjects with OSA, when compared with those without OSA, suggesting that this gene polymorphism may increase the risk of inflammation in these obese Asian Indians with OSA. However, these data need to be evaluated in a larger number of subjects.
TNFa acts through nuclear factor kappa-B (NF Kappa B) pathway and a recent study shows that NF Kappa B activation occurs in OSA, which in turn may contribute to pathogenesis of atherosclerosis, frequently seen in subjects with OSA. 11, 31, 32 TNFa has been found to be a direct mediator of inflammation in atherosclerotic lesions. 33 Serum levels of TNFa and of other inflammatory markers like Interlukin-6 (IL-6) and CRP correlate significantly with common carotid intima-media thickness (IMT) in healthy subjects, indicating association with early atherosclerosis. 34, 35 Asian Indians are highly predisposed to develop CHD due to multiple factors. 36 To this list, OSA may now be added, particularly in view of our data showing high levels of TNFa in these subjects. It is important to note that TNFa levels have been found to be a predictor of incident cardiovascular events and all-cause mortality. 37 Whether, high serum levels of TNFa in obese Asian Indians with OSA accurately predict and contribute to increase cardiovascular risk needs to be investigated in prospective studies.
Whether TNFa level is involved in pathogenesis of OSA or is a result of physiological disturbances due to OSA is not clearly known. However, mechanisms linking increase in levels of serum TNFa in OSA subjects may probably include repetitive hypoxemic stress and sleep deprivation. 7 Also, intermittent hypoxia, a major characteristic of OSA, has been reported to be the strongest predictor of TNFa levels. 7 The present study shows that obese subjects with OSA have significantly higher frequency of TNFa (À308A) allele and TNFa levels correlate with the severity of OSA. Few studies suggest sexual dimorphism in TNFa levels. 38 Logistic regression analysis suggested that raised TNFa levels in our study were not due to gender difference.
Population stratification may be responsible for observed association of TNFa À308A allele with OSA. Genotype frequencies of obese subjects without OSA were in HardyeWeinberg equilibrium, justifying against error by population stratification. Previous studies suggest that in association studies, population stratification can be detected by using unlinked genetic markers. 39 We studied two polymorphisms (Apolipoprotein E, E2, E3, E4 and Neuropeptide Y; Leu7Pro) for association with OSA. These genes are not known to be in linkage disequilibrium with TNFa gene. We did not find their increased frequency in subjects with OSA and their genotypic distributions were in HardyeWeinberg equilibrium. The numbers of markers studied were not sufficient to perform the population stratification test. Few studies have also shown that error rate by population stratification is very small in such epidemiological studies. 40, 41 Power of the study was 73.7% in allelic frequency and 100% power was obtained in serum TNFa level and AHI.
Logistic regression analysis suggested that gender difference was not a confounding factor; however, the calf circumference, 2 h-BG and serum TNFa levels were found to be confounding factors for OSA in these subjects. These findings suggest that the raised TNFa levels were not by chance and were linked with OSA.
There are certain limitations of our study. We did not have the data on siblings and other ancestral members of these subjects to detect the exact effect of population stratification. We were not having the data on other population controls as well. Clinically it is suggested to find out a marker linked with increased risk of OSA (e.g. cardiovascular diseases). We restricted the recruitment of study subjects to obese with and without OSA and excluded subjects with other diseases to see an independent effect of TNFa levels on OSA. The strength of the present study is that, to nullify the effect of obesity, subjects were carefully matched for BMI and %BF. All subjects were studied in the same sleep laboratory and sleep study analysis was done by single expert using standard analysis instructions. Further, subjects were carefully selected to avoid effect of any apparent acute or chronic inflammatory disease or infections.
Finally, more research questions based on our data need answers. There are evidences that TNFa level decreases after treatment of OSA with continuous positive airway pressure (CPAP). 42 For instance, whether treatment of OSA in our subjects with CPAP will lead to decrease in serum TNFa levels needs to be investigated. The effect of interventions such as weight loss and new therapies of metabolic syndrome (e.g. endocannabinoid receptor-1 blocker, Rimonabant) on TNFa levels needs to be investigated. Finally TNFa (À308G/A) polymorphism should be investigated as candidate gene polymorphism for OSA in other ethnic groups.
